Journals / Journal of Surgery and Medicine / 2021 / Cilt: 5 - Sayı: 1

Comparison of biopsy results of HPV 16/18 and non-16/18 HPV positive patients with a normal PAP test, a tertiary center experience

Pages
41–45
Publication Date
2021-01-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Direct referral of the patients, who are expected to be lost to follow-up, could be convenient for non-16/18 HPV positive patients with negative cytology to reduce progression of cervical cancer and the psychological burden of HPV positivity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aim: Optimal management for HPV positive and cytology negative patients remains a controversial issue.
📊
Key Findings & Data:Immediate colposcopy is suggested for HPV 16/18 positive patients, whereas patients with non 16/18 HPV oncogenic virus positive are recommended to co-test after a year.
💡
Conclusion & Impact:Conclusion: Direct referral of the patients, who are expected to be lost to follow-up, could be convenient for non-16/18 HPV positive patients with negative cytology to reduce progression of cervical cancer and the psychological burden of HPV positivity.
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:HPV 16 · HPV 18 · colposcopy

Abstract

Background/Aim: Optimal management for HPV positive and cytology negative patients remains a controversial issue. Immediate colposcopy is suggested for HPV 16/18 positive patients, whereas patients with non 16/18 HPV oncogenic virus positive are recommended to co-test after a year. In this study, we aim to compare the immediate colposcopic biopsy results between HPV 16/18 and non-16/18 HPV positive patients with cytology negative patients. Methods: In this prospective cross-sectional study, we included 1028 HPV positive and cytology negative patients who were screened for cervical cancer between January 2017 and 2019. Liquid based preparations were used for cytology samples (ThinPrep Pap Test). Cervical specimens were analyzed with Hybrid Capture for HPV types. Patients underwent colposcopic examination, biopsy procedure and endocervical curettage. Results: A total of 424 (41.2%) patients were HPV 16/18 positive, while 604 (58.8%) were non-16/18 oncologic HPV positive. Colposcopic biopsy results of the patients revealed that of the HPV 16/18 positive patients, 246 (23.9) had no dysplasia, 101 (9.8) had LGSIL and 77 (7.5%) had HGSIL. Among the non 16/18 positive patients, 422 (41.1%) had no dysplasia, 144 (14%) had LGSIL and 38 (3.7) had HGSIL. All patients were referred for endocervical curettage, which resulted as follows: Among HPV 16/18 patients, 384 (37.4%) had no dysplasia, 21 (2%) had LGSIL and 19 (1.8%) had HGSIL. Five hundred seventy-one non 16/18 positive patients had no dysplasia, 26 (2.5%) had LGSIL and 7 (0.7) had HGSIL. The comparison of colposcopic biopsy results of HPV 16/18 and non-16/18 HPV positive patients were different in terms of no dysplasia and HGSIL (P=0.001 and P=0.001, respectively), while LGSIL results were similar. The endocervical curettage biopsy results of the patients revealed a significant difference in HGSIL results (P=0.03). The two groups were similar with respect to reports of no dysplasia and LGSIL. Conclusion: Direct referral of the patients, who are expected to be lost to follow-up, could be convenient for non-16/18 HPV positive patients with negative cytology to reduce progression of cervical cancer and the psychological burden of HPV positivity.

🔖

Cite This Article

KOYUNCU, K., KURT, M., SAKİN, Ö., AKALIN, E. E., DENİZLİ, R., ÖKTEM, A., ALAN, Y., GÖKKAYA, M. (2021). Comparison of biopsy results of HPV 16/18 and non-16/18 HPV positive patients with a normal PAP test, a tertiary center experience. Journal of Surgery and Medicine, Cilt: 5 - Sayı: 1, 41–45. https://ajindex.com/articles/780107

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncology. 2010;11(11):1048-56. Epub 2010/10/15. doi: 10.1016/S1470-2045(10)70230-8. Pubmed PMID: 20952254
  2. Tilston P. Anal human papillomavirus and anal cancer. Journal of Clinical Pathology. 1997;50(8):625-34. doi: 10.1136/jcp.50.8.625. Pubmed PMID: 9301544
  3. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709-20. doi:10.1093/jnci/92.9.709. PMID: 10793107
  4. Thomsen LT, Kjær SK, Munk C, Frederiksen K, Ørnskov D, Waldstrøm M. Clinical Performance of Human Papillomavirus (HPV) Testing versus Cytology for Cervical Cancer Screening: Results of a Large Danish Implementation Study. Clinical Epidemiology. 2020;12:203-13. Epub:2020/2/21 doi: 10.2147/CLEP.S243546. Pubmed PMID: 32110112 5. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. Journal of National Cancer Institute. 2008;100(20):1432-8. Epub: 2008/10/7. doi: 10.1093/jnci/djn326. PMID: 18840817 6. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. Journal of National Cancer Institute. 2001;93(14):1054-61. doi: 10.1093/jnci/93.14.1054. PMID: 11459866
  5. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncology. 2011;12(7):663-72. doi: 10.1016/S1470-2045(11)70145-0. PMID: 21684207 8. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al.Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003 6;362(9399):1871-6 PMID: 14667741 9. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. Journal of Low Genital Tract Disease. 2007;11(4):201-22. doi: 10.1097/LGT.0b013e31